INTRODUCTION
============

Life cycle--stage developmental regulation is essential for the transmission of trypanosomatid pathogens and includes morphological, transcriptional, and physiological adaptations for survival in the host and the vector ([@B33]). *Trypanosoma brucei is* transmitted by tsetse flies and causes human African trypanosomiasis and related cattle diseases in sub-Saharan Africa ([@B47]). In the mammalian host, *T. brucei* proliferates as slender bloodstream forms (BFs) and undergoes antigenic variation by expressing variant surface glycoproteins (VSGs), thus avoiding host antibody clearance ([@B12]). BFs rely solely on glycolysis for energy production, and many glycolytic enzymes are in peroxisome-like organelles called glycosomes ([@B24]; [@B26]). In the mammalian bloodstream, the slender BFs develop into nonreplicating stumpy BFs, which then develop into procyclic forms (PFs) after transmission to the fly ([@B33]; [Figure 1A](#F1){ref-type="fig"}). The transition entails morphological and metabolic changes, including a switch from glycolysis to oxidative phosphorylation ([@B5]), and changing the surface coat from VSGs to procyclins ([@B41]). Different procyclins appear to be expressed in a particular order after *T. brucei* infection of tsetse flies ([@B55]), although that may differ between *T. brucei* strains or in vivo versus in vitro ([@B41]; [@B56]; [@B3]). Other developmental changes accompany the life-cycle progression in the fly from PFs to epimastigotes and then to mammalian infective metacyclic trypomastigotes.

![IPMK regulates development of BF *T. brucei* to PF. (A) Diagram of the *T. brucei* life cycle stages. Long slender BFs (1) differentiate to short stumpy BFs (2). BFs after ingestion by tsetse flies differentiate to PFs and then to epimastigotes (4) and metacyclics (MFs) (5), which are infectious to mammals. BFs and MFs express VSGs; PFs express procyclins; epimastigotes expresses brucei alanine-rich proteins (BARPs); and stumpy expresses PAD1. (B) Diagram of a portion of the IP pathway. IP5K, inositol pentakisphosphate kinase; IP6K, inositol hexakisphosphate kinase; IP5Pase, inositol polyphosphate 5-phosphatase; IMPase, inositol monophosphatase. See *Materials and Methods* for gene IDs and additional abbreviations. (C) Morphological quantification of *T. brucei* BFs and PFs. IPMK was either expressed or knocked down for 36 h in *T. brucei* BF in HMI-9 at 37°C, followed by transfer to SDM-79 at 27°C (time 0). Top, continuous IPMK expression (tet +); middle, continuous IPMK knockdown (tet --); and bottom, IPMK was reexpressed after 36 h knockdown, at the transfer to SDM-79 at 27°C (tet --/+). Transition forms were counted as BFs. (D) Quantification as a percentage of CN cells that developed PF morphology after gene knockdown. IPMK, PIP5K, PIP5Pase 1, or CDS were either expressed or knocked down, as described in C, and quantification of cells with PF morphology were done at day 8. (E) Flow cytometry analysis of VSG or EP procyclin expression after IPMK knockdown in *T. brucei* BF in HMI-9 at 37°C for 36 h or SDM-79 for 3 d, respectively. (F) Western blot analysis of VSG or EP procyclin expression after IPMK knockdown in *T. brucei* BF. Top, BFs were collected in late-log growth in HMI-9 at 37°C for 24 h (1.5 × 10^6^ cells/ml) and 48 h (2.5 × 10^6^ cells/ml), respectively. Bottom, BFs were collected in mid--log growth (8.0 × 10^5^ cells/ml) in HMI-9 at 37°C for 24 h and then transferred to SDM-79 at 27°C for an additional 12 and 36 h. Western blots were run with 1.0 × 10^7^ cells (top) and 5.0 × 10^6^ cells equivalents/lane (bottom). Blots were stripped and reblotted with monoclonal antibodies (mAb) α-HSP70. (G) EP procyclin IF analysis after IPMK knockdown and 4 d in SDM-79 at 27°C as described in C. Differential interference contrast (DIC) image shows *T. brucei* (tet-) with PF morphology, and IF shows surface EP procyclin expression. The pictures are representative of three independent experiments. Blue, DAPI staining of DNA; green, EP procyclin. Bar, 10 µm. Tet, 0.5 µg/ml. Data are represented as mean ± SEM.](mbc-29-1137-g001){#F1}

Cell signaling and metabolic changes are implicated in regulating development between life-cycle stages. The AMP-activated protein kinase (AMPK) complex functions as an AMP/ATP sensor and regulates development of stumpy forms ([@B43]). AMP and cAMP analogues, which inhibit TbTOR4 expression, induce development of BF slender to stumpy, as does knockdown of TbTOR4 ([@B2]). In contrast, knockdown of a Nek-related kinase or protein phosphatase 1 inhibits stumpy formation ([@B35]; [@B19]). Moreover, expression of metabolic enzymes and mitochondrial enzyme activities are altered during *T. brucei* development ([@B57]; [@B19]). Tricarboxylic acid (TCA) cycle metabolites citrate and *cis*-­aconitate (CCA) and a temperature shift from 37 to 27°C stimulate development of BFs to PFs and activation of oxidative metabolism ([@B37]). CCA is transported by the carboxylate transporter proteins associated with differentiation (PAD), which is expressed in stumpy BFs and PFs ([@B17]). CCA inhibits activation of the protein tyrosine phosphatase TbPTP1, which is a negative regulator of BF-to- PF development, by the protein phosphatase TbPIP39 resulting in BF-to-PF development ([@B52]). Other treatments have been shown to stimulate BF-to-PF development, such as mild acid ([@B42]) or protease treatment ([@B61]). Mild acid was shown to affect TbPIP39 phosphorylation, whereas protease treatment appeared to affect an alternate process that is dispensable in tsetse flies ([@B51]). The RNA-binding proteins (RBPs) RBP6, RBP7, and RBP10 are also implicated in *T. brucei* development, likely by regulating stage-­specific transcript expression ([@B35]; [@B30]; [@B60]). Hence, *T. brucei* development employs multiple processes including signaling, metabolism, and control of gene expression to coordinate changes in parasite morphology, surface composition, and physiological adaptations to the host and vector.

We showed that the inositol phosphate (IP) pathway controls telomere silencing and allelic exclusion of VSG expression sites (ES) ([@B11]), which is developmentally regulated in *T. brucei*. IPs function as second messengers via interactions with proteins that regulate many metabolic and developmental processes in eukaryotes ([@B50]; [@B13]; [@B45]; [@B59]). The IP pathway enzymes catalyze the synthesis and phosphate remodeling of IPs and phosphatidylinositols (PIs). A PI-specific phospholipase C (PLC) cleaves PI(4,5)P2 to generate diacylglycerol and Ins(1,4,5)P3. We showed that Ins(1,4,5)P3 is further converted by *T. brucei* IP multikinase (IPMK) to Ins(1,3,4,5)P4 and Ins(1,3,4,5,6)P5 ([Figure 1B](#F1){ref-type="fig"}; [@B8]). We show here that the IP pathway functions in the control of *T. brucei* development. Specifically, IPMK knockdown in BFs resulted in loss of surface VSGs and expression of a procyclin surface coat, a metabolic switch from glycolysis to oxidative phosphorylation, a shift from the BF to PF stage specific transcriptome, and development of PF morphology. The expression of a kinase-dead IPMK also resulted in BF-to-PF development, indicating that IPMK enzymatic activity, and likely its substrates or products, is involved in these processes. We found that proteins that interact with Ins(1,4,5)P3 or Ins(1,3,4,5)P4 have functions associated with various cellular processes that differ between stages and thus may be controlled by these metabolites. We propose that IPs may be part of a regulatory system that controls *T. brucei* metabolism and development.

RESULTS
=======

IPMK regulates BF-to-PF development in *T. brucei*
--------------------------------------------------

To identify the role of IPs in *T. brucei*, we generated a conditional null (CN) IPMK cell line by removing both endogenous IPMK alleles and inserting a tetracycline (tet)-regulatable IPMK allele into the ribosomal DNA spacer ([@B11]). Knockdown of IPMK resulted in BFs developing to PFs ([Figure 1C](#F1){ref-type="fig"}). IPMK was knocked down by withdrawal of tet, and after 36 h, a time point in which cell viability were \>90% (Supplemental Figure S1, A--C), the cells were transferred from BF (HMI-9 at 37°C) to PF (SDM-79 at 27°C) growth conditions, and parasite survival and development to PFs were monitored by cell morphology and procyclin expression. The IPMK knockdown resulted in nearly half of the cells surviving under PF conditions, whereas essentially all IPMK-expressing cells remained as BFs and eventually died ([Figure 1C](#F1){ref-type="fig"}). In addition, ∼40% of the surviving cells developed into morphological PFs over time ([Figure 1, C and D](#F1){ref-type="fig"}). During this period of time, the BF cell population gradually decreased concomitant with an increase in the PF cell population. IPMK knockdown under BF growth conditions for 36 h resulted in loss of VSG2 expression in ∼42% of the cell population ([Figure 1E](#F1){ref-type="fig"}). In addition, the proportion of cells expressing PAD1, which increased from 45% to 60% between 24 and 36 h when IPMK was expressed, declined from 49% to 23% in IPMK knockdown cells (Supplemental Figure S1D). Western blot analysis showed a gradual increase in EP procyclin expression in BFs growing at late log (24 h) and stationary (48 h) phases, especially after IPMK knockdown ([Figure 1F](#F1){ref-type="fig"}, top panel), but not in BFs at mid--log growth (24 h; [Figure 1F](#F1){ref-type="fig"}, bottom panel). The IPMK knockdown also increased EP procyclin expression after transfer to PF conditions, which was accompanied by a decrease in VSG expression ([Figure 1F](#F1){ref-type="fig"}, bottom panel). After 3 d, ∼70% of the population expressed EP procyclins ([Figure 1E](#F1){ref-type="fig"}), and immunofluorescence (IF) analysis showed EP procyclin surface expression by cells with PF morphology ([Figure 1G](#F1){ref-type="fig"}). IPMK reexpression after 36 h knockdown under BF conditions followed by transfer to PF conditions resulted in ∼30% of cells with PF morphology compared with 40% when IPMK was continuously knocked down ([Figure 1C](#F1){ref-type="fig"}). The data indicate that IPMK knockdown resulted in cells committed to develop into PFs. However, overexpression of IPMK had no effect on *T. brucei* BF development (Supplemental Figure S1E). Knockdown of other genes of the IP pathway, PI 5-kinase (PIP5K), PI 5-phosphatase (PIP5Pase 1), or CDP-diacylglycerol synthase (CDS), all of which have growth kinetics similar to that of IPMK CN ([@B11]), did not result in development of BF to PFs ([Figure 1D](#F1){ref-type="fig"}), which suggests that the development phenotype is related to perturbation of a specific step of the pathway, the IPMK step, and not nonspecific effects due to gene knockdown, viability, or tet. Notably, the parental cell line SM427 differentiates into PFs that survive in PF culture for ∼21 d but for unknown reasons are not continuously cultivatable. Exclusive expression of *T. cruzi* or *L. major* IPMK orthologues, which rescued *T. brucei* from the lethal IPMK knockdown in BFs ([@B8]), only partially reverted development rates (Supplemental Figure S1F), likely due to IPMK sequence differences among these species. Our data suggest that IPMK regulate development of *T. brucei* BF to PF.

Development of BFs to PFs depends on IPMK catalytic activity
------------------------------------------------------------

To determine whether IPMK catalytic activity is required for *T. brucei* BF development to PF, we generated mutations in the predicted IPMK catalytic site to eliminate its activity. *T. brucei* IPMK has some amino acids (aa) within the catalytic site that are conserved with IPMKs from yeast, humans, and *Arabidopsis* ([Figure 2](#F2){ref-type="fig"}A), despite the overall low aa conservation (aa identities are 23.3%, 22.6%, and 24.9%, respectively). The D131A and/or K133A mutations within the yeast IPMK catalytic site have been shown to eliminate its activity ([@B20]; [@B6]), whereas a K121W mutation in *Arabidopsis thaliana* IPMK was shown to selectivity eliminate its 6-kinase activity ([@B21]). Hence, we expressed in *Escherichia coli* and purified the following his-tagged recombinant versions of *T. brucei* IPMK: wild type (WT), D142A (equivalent to yeast D131A), D142/D144A (equivalent to yeast D131A/K133A), and K164W (equivalent to *A. thaliana* K121W; [Figure 2B](#F2){ref-type="fig"}). Enzymological analysis showed that the D142A mutation reduced but did not eliminate IPMK activity. Specifically, the *K*~m~ value for Ins(1,4,5)P3 was increased from 61.4 to 113.0 µM and the *K*~m~ value for Ins(1,3,4,5)P4 was increased from 91.4 to 153.5 µM ([Figure 2C](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). While the K164W mutation did not significantly affect Ins(1,4,5)P3 phosphorylation, it increased the *K*~m~ value for Ins(1,3,4,5)P4 from 91.4 to 169.9 µM, implying that this mutation reduced 6-kinase activity. Importantly, the D142A/K144A double mutation eliminated IPMK activity on both Ins(1,4,5)P3 and Ins(1,3,4,5)P4 substrates. Exclusive expression of *T. brucei* V5-tagged WT, D142A, or K164W rescued the growth of the *T. brucei* IPMK CN, whereas exclusive expression of V5-tagged D142A/K144A IPMK did not ([Figure 2, D and E](#F2){ref-type="fig"}), indicating that IPMK catalytic activity is essential for *T. brucei* growth. Exclusive expression of the D142A/K144A mutant also resulted in a significant increase in BF to PF development compared with that for cells expressing WT IPMK ([Figure 2F](#F2){ref-type="fig"}), whereas expression of either the D142A or K167W mutant only slightly affected development. Hence, development of BF to PF results from the loss of IPMK catalytic activity as well as the elimination of IPMK protein.

![Development of BFs to PFs depends on IPMK catalytic activity. (A) Alignment of catalytic sites of IPMKs of *T. brucei*, *A. thaliana* (gene ID: AED91147.1)*, Homo sapiens* (gene ID: NP_689416.1), and *Saccharomyces cerevisiae* (gene ID: PJP09331.1). Mutated sites are shown in red. (B) Recombinant *T. brucei* IPMK WT or mutants (37 kDa) resolved on a 4--20% SDS--PAGE gel stained with Coomassie Imperial Staining (Pierce). (C) Activity analysis of rIPMK WT and mutants with Ins(1,4,5)P3 and Ins(1,3,4,5)P4 substrates. See [Table 1](#T1){ref-type="table"} for kinetic parameters of each rIPMK enzyme and substrates. Growth curve (D) and Western blot analysis (E) of *T. brucei* IPMK CN exclusively expressing V5-tagged IPMK WT, mutants D142A, K164W, D142A/K144A, or no IPMK gene (knockdown). Cells were grown in the absence of tet for exclusive expression of introduced V5-tagged WT, mutant allele, or IPMK knockdown. Blots were stripped and reblotted with mAb 78, which recognizes mitochondrial HSP70. (F) Flow cytometry analysis and quantification of *T. brucei* expressing EP procyclin after IPMK knockdown or exclusive expression (EE) of WT or mutant IPMK alleles for 36 h in HMI-9 at 37°C in BF followed by 6 d in SDM-79 at 27°C.](mbc-29-1137-g002){#F2}

###### 

Kinetic parameters of WT and mutant *T. brucei* rIPMK.

                                   Wild type        D142A            K164W            D142A/K144A
  -------------------------------- ---------------- ---------------- ---------------- -------------
  Ins(1,4,5)P3                                                                        
  *K*~m~ (µM)                      61.41 (±15.37)   113.0 (±31.93)   51.04 (±13.84)   ND
  V~max~ (nmol/min per µg)         617.0 (±62.64)   660.2 (±92.97)   629.6 (±65.16)   ND
  *K*~cat~/*K*~m~ (S^--1^M^--1^)   1.67 × 10^5^     9.73 × 10^4^     2.06 × 10^5^     ND
  Ins(1,3,4,5)P4                                                                      
  *K*~m~ (µM)                      91.44 (±52.01)   153.5 (±33.97)   169.9 (±20.39)   ND
  V~max~ (nmol/min per µg)         400.8 (±52.01)   315.2 (±38.48)   540.3 (±36.96)   ND
  *K*~cat~/*K*~m~ (S^--1^M^--1^)   7.31 × 10^4^     3.42 × 10^4^     5.23 × 10^4^     ND

ND, not determined. The D142A/K144A mutation eliminates enzyme activity.

IPMK knockdown affects stage-specific patterns of gene expression
-----------------------------------------------------------------

To investigate how IPMK affects *T. brucei* development, we collected RNA at 24 and 36 h after IPMK knockdown in BF conditions, times during which cells are growing and viable (Supplemental Figure S1, A--C), and performed transcriptomic analysis by RNA sequencing (RNAseq). While many genes were differentially regulated at 24 h, the most significant changes were at 36 h, that is, within four to six cell divisions, with ∼1500 genes differentially regulated ([Figure 3A](#F3){ref-type="fig"} and Supplemental Dataset 1; fold change ≥2, *p* value ≤ 0.05). We performed gene set enrichment analysis (GSEA) of the 36-h RNAseq data using sets of genes that are differentially expressed between *T. brucei* stages ([@B7]). We found a significant enrichment in gene sets from BF (*q* = 1.6 × 10^--14^), from PF (*q* = 8.4 × 10^--7^), and to a lesser extent from intermediate forms (*q* = 1.6 × 10^--3^; [Figure 3B](#F3){ref-type="fig"}), implying changes in the expression of stage-specific genes. In addition, we found that ∼^1^⁄~3~ of the top ∼400 genes that had been shown by ribosome profiling to be up-regulated in BFs or PFs ([@B27]) were also up-regulated after 36 h of IPMK knockdown ([Figure 3C](#F3){ref-type="fig"}). We randomly selected a subset of 44 genes from the BF and PF gene sets and validated their differential expression by real-time PCR after IPMK knockdown ([Figure 3D](#F3){ref-type="fig"}). Knockdown of SYJ 2 or IMPase 2 enzymes, which are predicted to dephosphorylate IP or PI metabolites, did not affect expression of these gene sets, indicating that their regulation is dependent on IPMK expression ([Figure 3D](#F3){ref-type="fig"}). Gene ontology (GO) analysis of the 97 BF and 112 PF up-regulated genes ([Figure 3C](#F3){ref-type="fig"}) revealed that BF genes were associated with adenylate cyclase and signal transduction, surface receptors, response to stimulus, and antigenic variation ([Figure 3E](#F3){ref-type="fig"}). In contrast, PF genes were associated with amino acid and carboxylic acid transporters and metabolism, oxidative phosphorylation, and ATP biosynthesis ([Figure 3E](#F3){ref-type="fig"}). IPMK knockdown also affected expression of protein kinases and phosphatases, including those involved in development (Supplemental Dataset 1). An increase in VSG11 expression was also detected at 24 h after IPMK knockdown ([Figure 3A](#F3){ref-type="fig"}) followed by up-regulation of other telomeric and nontelomeric VSG genes at 36 h (Supplemental Figure S2). This suggests that, in addition to changes from VSG to procyclins ([Figure 1](#F1){ref-type="fig"}), some cells in the population either lost expression site regulation or switched VSG expression. Given the role of the IP pathway in regulating VSG allelic exclusion and antigenic switching ([@B11]), it is likely that IPMK knockdown affected IP steady state levels and thus VSG regulation. Notably, knockdown of PIP5K or PIP5Pase 1 ([@B11]), both of which are involved in the regulation of VSG expression, did not result in BF-to-PF development ([Figure 1D](#F1){ref-type="fig"}), and hence IPMK effects on cell development is unlikely to be due to ES derepression or to lethal effects resulting from knockdown of these essential genes.

![IPMK knockdown alters stage-specific gene expression in *T. brucei*. (A) Volcano plot shows differentially expressed (DE) genes after IPMK knockdown at 24 and 36 h by RNAseq. See Supplemental Dataset S1 for RNAseq data. Arrows indicate IPMK. RNAseq data of knockdown (tet --) IPMK cells were compared with tet + cells at their respective time points (24 or 36 h). (B) Barcode plot shows GSEA of genes up-regulated in BF or PF (top) or up- and down-regulated in stumpy (middle) or intermediates (bottom) in the 36-h RNAseq data. Each bar indicates a gene of the set and its location on the *x*-axis is its fold change. ES, enrichment score (see Supplemental Information text for details on gene sets). False discovery rates (*q*) are indicated for each gene set analysis. (C) Expression profile in the 36-h IPMK knockdown RNAseq data of the top ∼400 translated genes of BF or PF ([@B27]). (D) Real-time PCR analysis of 44 genes selected from BF or PF gene sets after 30 h knockdown of IPMK, SYJ 2, or IMPase 2 in *T. brucei* BFs. (E) Gene ontology (GO) enrichment analysis of the 97 BF and 112 PF up-regulated genes shown in C. Tet, 0.5 µg/ml. Enrichment represents the percentage of genes in BF or PF sets that are associated with a GO process divided by the percentage of genes of the same process in the genome. Data are represented as the mean.](mbc-29-1137-g003){#F3}

IPMK knockdown also affected the expression of many RBP mRNAs, such as up-regulation of RBP6, RBP7A and B, and PPCT1 ([Figure 4A](#F4){ref-type="fig"}). Real-time PCR analysis confirmed RBPs' differential expression ([Figure 4B](#F4){ref-type="fig"}), whereas knockdown of other IP pathway genes did not similarly affect their expression. Overexpression of RBP6-V5 in BFs down-regulated the expression of gene sets under BF conditions for 24 h, but up-regulated their expression if BFs were cultured under PF conditions for 36 h ([Figure 4C](#F4){ref-type="fig"}). Moreover, overexpression of PPCT1-V5 or RBP7A-V5 in BFs resulted in differential expression of the genes sets in a manner dependent on growth conditions. Hence, these RBPs affect expression of genes that are differentially expressed between BFs and PFs, and their effects on transcript abundances are dependent on growth conditions. Overexpression of RBP6, RBP7A, RBP7B, or PPCT1 in BFs did not result in development of BFs to PFs ([Figure 4, D and E](#F4){ref-type="fig"}). However, EP procyclin expression decreased by ∼35% when RBP6-V5 was overexpressed, with concomitant induction of BF-to-PF development by CCA ([Figure 4, D and E](#F4){ref-type="fig"}). This suggests that RBP6 may function as a negative regulator of BF-to-PF development, in addition to its overexpression resulting in PF-to-MF development ([@B30]). Hence, these RBPs may play various complementary roles in *T. brucei* development that are affected by IPMK knockdown. Overall, IPMK knockdown alters expression of genes involved in metabolism, signaling, control of gene expression, and development in *T. brucei*.

![RBPs associated with stage specific gene regulation. (A) Differential expression of RBPs after knockdown of IPMK (36 h) or other IP pathway genes (24 h). (B) Real-time PCR analysis of 10 selected RBPs after 24 and 36 h IPMK knockdown. (C) Real-time PCR analysis of 44 genes from BF and PF gene sets after tet-regulatable overexpression of C-terminally V5-tagged RBPs in *T. brucei* BFs cultured in HMI-9 at 37°C for 24 h or SDM-79 at 27°C for 36 h. (D) Flow cytometry analysis of EP procyclin expression in *T. brucei* BFs overexpressing RBP6-V5 or PPCT1-V5. Cells were incubated in SDM-79 at 27°C for 3 d. (E) Flow cytometry quantification of EP procyclin expression after RBPs overexpression in *T. brucei* BFs (as described in D). Tet, 1 µg/ml. Data are represented as mean (heat maps) or mean ± SEM (bar graphs).](mbc-29-1137-g004){#F4}

Ins(1,4,5)P3- and Ins(1,3,4,5)P4-interacting proteins function in cell signaling, metabolism, and regulation of protein synthesis
---------------------------------------------------------------------------------------------------------------------------------

Because IPMK phosphorylates Ins(1,4,5)P3 to generate Ins(1,3,4,5)P4 initially ([Figure 1B](#F1){ref-type="fig"}; [@B8]), we sought to identify proteins that might interact with these IPs by affinity purification of *T. brucei* BF proteins using IPs or PIs conjugated with agarose beads that are commercially available or with nonconjugated beads as a control ([@B28]; [@B59]). Out of ∼1200 proteins detected by mass spectrometry, 129 (fold change ≥ 2, *p* value \< 0.1) were identified by label-free quantitative analysis associated with each metabolite in multiple experiments when compared with nonconjugated beads ([Figure 5, A and B](#F5){ref-type="fig"}; Supplemental Dataset 2). Eighty-five proteins interacted with Ins(1,4,5)P3, 109 with Ins(1,3,4,5)P4, and 68 of these with both IPs, although the enrichment values of these 68 proteins were higher with Ins(1,3,4,5)P4 than with Ins(1,4,5)P3 ([Figure 5, C and D](#F5){ref-type="fig"}). Other true interactions may not have been identified due to the stochastic nature of mass spectrometry analysis, which often results in variable detection of less abundant proteins, or less frequently detected peptides, deemed not significant in statistical analysis ([@B15]); or due to other factors that may affect protein interactions after cell lysis, such as changes in protein conformation or protein complex stability. Nevertheless, the statistical analysis provides a list of potential IP--protein interactions. Affinity purification with biotin-conjugated Ins(1,4,5)P3 or Ins(1,3,4,5)P4 followed by Western blot analysis confirmed the interactions of V5-tagged cysteinyl-tRNA synthetases (CysRS), phosphoglycerate kinase C (PGKC), peroxisomal membrane protein 14 (PEX14), heat shock protein 70 (HSP70), and universal minicircle sequence--binding protein (UMSBP1) with Ins(1,3,4,5)P4, and the interactions of V5-tagged intraflagellar transport proteins 54/57 (IFT54/57), HSP70, and UMSBP1 with Ins(1,4,5)P3 (Supplemental Figure S3). We also performed affinity purification and mass spectrometry to identify proteins that bound to agarose-conjugated PI(3,4,5)P3 to control for potential nonspecific IP--protein binding due to, for example, IP charges. The IP configuration of PI(3,4,5)P3 is similar to that of Ins(1,3,4,5)P4, except that phosphate 1 of the inositol ring is linked to a diacylglycerol moiety. Thirty-three proteins (fold change ≥ 2, *p* value \< 0.1) were found to interact with PI(3,4,5)P3 when compared with the set interacting with agarose beads alone, 22 of which also interacted with Ins(1,4,5)P3 and 25 with Ins(1,3,4,5)P4 ([Figure 5, A--D](#F5){ref-type="fig"}). The detection of a protein interacting with more than one IP ([Figure 5C](#F5){ref-type="fig"}) may be due to flexible protein domain requirements for IP binding ([@B32]), which may involve specific protein regions and which may be affected in vivo by subcellular concentrations and by locations and interactions of the proteins and substrates. The annotated functions of these proteins identified processes including metabolism, translation, protein folding and degradation, cytoskeleton, trafficking, flagellum organization, and nuclear function, and only ∼6% of the 129 proteins had been annotated as hypothetical (unknown function; [Figure 5, B and C](#F5){ref-type="fig"}). GO analysis indicated that the Ins(1,4,5)P3-specific proteome was enriched in proteins with functions associated with cell motility, which were also present in the common subset of 68 proteins, whereas that of Ins(1,3,4,5)P4 was enriched in proteins with metabolic functions some of which were also in the common subset ([Figure 5E](#F5){ref-type="fig"}). More proteins with metabolic functions were associated with Ins(1,3,4,5)P4 than with Ins(1,4,5)P3 or PI(3,4,5)P3, which included proteins involved in glycolysis, amino acid and purine metabolism, the TCA cycle, and antioxidants (AOS; [Figure 5F](#F5){ref-type="fig"}). Hence, Ins(1,4,5)P3 and Ins(1,3,4,5)P4 binding are associated with cell signaling, metabolism, and protein synthesis and turnover and are potentially involved in regulating these processes.

![Proteomic analysis of inositol phosphate interacting proteins. (A) Volcano plots indicate proteins that interact with Ins(1,4,5)P3 or Ins(1,3,4,5)P4 compared with nonconjugated beads (enrichment cutoff ≥ 2-fold and *p* value \< 0.1). See Supplemental Dataset S2 for list of proteins. (B) Fold enrichment analysis of proteins that interact with each IP by functional categories. (C) Network analysis of protein IP interactions. Blue line, Ins(1,3,4,5)P4 interactions; red line, Ins(1,3,4)P3 interaction; gray line, proteins that interact with both IPs. (D) Ratio of fold enrichment of proteins identified as interacting with Ins(1,3,4,5)P4 vs. Ins(1,4,5)P3. (E) GO enrichment analysis of proteins interacting with Ins(1,4,5)P3, Ins(1,3,4,5)P4, or both. (F) Heat map of metabolic proteins that interact with each IP (subset indicated by brackets in B). Fold enrichment values are indicated for each protein.](mbc-29-1137-g005){#F5}

IPMK regulates oxidative phosphorylation inhibitor--sensitive ATP production in BFs
-----------------------------------------------------------------------------------

The affinity enrichment of proteins involved in energy metabolism by Ins(1,3,4,5)P4 suggests that the IPMK knockdown may affect, among other processes, cellular energy metabolism. *T. brucei* BF relies solely on glycolysis for energy production, consuming glucose to generate ATP and excreting pyruvate ([Figure 6A](#F6){ref-type="fig"}). Knockdown of IPMK in BFs (under BF growth conditions) resulted in an increase in ATP levels that was 2.5-fold by 48 h, whereas knockdown of eight other IP pathway genes did not significantly affect ATP levels ([Figure 6B](#F6){ref-type="fig"}). Exclusive expression of the catalytically inactive version of IPMK harboring the D142A/K144A mutations or the partially active D142A mutant also resulted in increased ATP levels, whereas exclusive expression of the K164W mutant (which partially affected 6-kinase activity) did not affect ATP levels ([Figure 6C](#F6){ref-type="fig"}). Notably, a decrease rather than an increase in ATP level is associated with loss of viability ([@B49]) and thus the ATP accumulation may result from changes in energy metabolism in these cells. In contrast, the amounts of pyruvate released into culture medium after 48 h IPMK knockdown were not significantly affected ([Figure 6D](#F6){ref-type="fig"}). The decrease in pyruvate release after PIP5Pase 1 knockdown correlates with its early growth defect ([@B11]). However, there was also a decrease in pyruvate release after knockdown of PIP5Pase 2 or IP5Pase and an increase after knockdown of SYJ 2 ([Figure 6C](#F6){ref-type="fig"}). Because these genes are not essential for *T. brucei* growth (Supplemental Figure S4; [@B8]), the effect of their knockdown may relate directly to perturbations of the IP pathway.

![IPMK regulation of *T. brucei* energy metabolism. (A) Diagram of *T. brucei* BF glycolysis. Some steps have been omitted for simplicity. FBP, fructose 1,6-biphosphate; DHAP, dihydroxyacetone phosphate; G3P, glycerol-3-phosphate; G3AP; glyceraldehyde 3-phosphate; BPG, 2,3-bisphosphoglyceric acid, PG, 3-phosphoglycerate; PEP, phosphoenolpyruvate; AOX, alternative oxidase; G3PDH, glyceraldehyde 3-phosphate dehydrogenase (or GAPDH). (B--D) Measurements of ATP produced per cell (B, C) or pyruvate released into medium (D) after 48 h knockdown of IP pathway genes (B, D) or exclusive expression of IPMK mutant alleles (C). (E) Quantification and (F) IF analysis of the number of BF glycosomes labeled with antibodies against PGK, aldolase, and GAPDH after 48 h knockdown of IPMK or IMPase. α-2481D recognizes glycosomal aldolase and GAPDH. The pictures are representative of six independent experiments. *n*, number of cells counted. (G) Western blot analysis of *T. brucei* BF lysates after 24 and 48 h IPMK knockdown. Polyclonal antibodies (pAb) α-PGK detect all three PGK isoforms. Blots were stripped and reblotted with mAb α-HSP70. Tet, 0.5 µg/ml. Data are represented as means. \**p* \< 0.05; \*\**p* \< 0.01, \*\*\**p* \< 0.005 comparing tet- vs. tet+ conditions or IPMK mutant vs. WT alleles by *t* test.](mbc-29-1137-g006){#F6}

Owing to the lack of feedback regulation of glycolytic enzymes in trypanosomes, ATP net production is controlled by compartmentalization of some glycolytic enzymes into glycosomes, and hence loss of glycosomes is toxic to BFs ([@B24]; [@B26]). Glycosomes of BFs were analyzed by three-­dimensional (3D) deconvolution IF microscopy of glycosomal PGK, aldolase, and GAPDH enzyme ([@B46]). IPMK knockdown for 48 h under BF conditions resulted in a decrease of PGK-labeled glycosomes per cell, and PGK had a somewhat dispersed rather than a punctate localization ([Figure 6, E and F](#F6){ref-type="fig"}). However, IPMK knockdown did not affect the expression levels of other glycosomal proteins or the overall number of glycosomes per cell ([Figure 6, E--G](#F6){ref-type="fig"}). Knockdown of IMPase 1, which did not affect pyruvate production ([Figure 6D](#F6){ref-type="fig"}), also did not affect PGK localization or glycosome numbers ([Figure 6E](#F6){ref-type="fig"}). *T. brucei* expresses glycosomal PGKA (56 kDa) in BF and PF, whereas the PGKC (47kDa) and PGKB (45 kDa) are developmentally regulated and expressed in the glycosomes of BF and in the cytosol of PF, respectively ([@B4]). Although this α-PGK antibody cannot distinguish PGK isoforms and size differences between PGKB and C cannot be resolved by Western blotting ([Figure 6G](#F6){ref-type="fig"}), real-time PCR showed down-regulation of PGKC mRNA levels (Supplemental Figure S5). Thus, the excess of ATP production and PGK localization is not due to loss of glycosomes but may be a consequence of metabolic and developmental changes in BFs.

Because of the elevated ATP levels ([Figure 6](#F6){ref-type="fig"}), we explored whether IPMK knockdown altered mitochondrial ATP production. RNAseq analysis after 36 h of IPMK knockdown revealed up-regulation of several genes encoding enzymes of the TCA cycle, fatty acid and ubiquinone metabolism, and the respiratory chain, including those encoding complexes II, III, and IV which are specific from *T. brucei* PFs ([Figure 7A](#F7){ref-type="fig"}). Knockdown (under BF growth conditions) of four other genes of the IP pathway, PIP5K, PIP5Pase 1, IP1Pase, and SYJ 2, did not significantly affect expression of these genes ([Figure 7A](#F7){ref-type="fig"}). Remarkably, the excess ATP produced after IPMK knockdown in BFs reverted to its normal levels, that is, no knockdown, in the presence of inhibitors of oxidative phosphorylation ([Figure 7B](#F7){ref-type="fig"}), including rotenone, antimycin, cyanide and sodium azide, and oligomycin, which inhibit complexes I, III, IV, and V, respectively. ATP production was also sensitive to SHAM, which indicates that these cells still depend on the alternative oxidase ([Figure 7B](#F7){ref-type="fig"}). The growth of *T. brucei* CN IPMK BF was unaffected by antimycin, K cyanide, or rotenone whether they express IPMK or not (Supplemental Figure S6), likely because these cells still have a functional glycolytic pathway for energy production. Hence, IPMK knockdown alters *T. brucei* ATP levels, likely by production of an active oxidative phosphorylation system in BFs, and possibly affects other metabolic pathways, all of which occurred in BFs and hence preceded their development to PFs.

![IPMK regulates oxidative phosphorylation inhibitor sensitive ATP production in BFs. (A) RNAseq analysis of metabolic genes after knockdown of IPMK (36 h) or other IP pathway genes (24 h). RNAseq data of knockdown (tet-) cells were compared with data on their respective nonknockdown (tet+) cells. (B) Measurements of ATP produced per cell after 48 h IPMK knockdown in absence or presence of oxidative phosphorylation inhibitors. Antimycin (8 mM), potassium cyanide (K cyanide, 50 µM), sodium azide (0.5 mM), rotenone (5 µM), oligomycin (50 ng/ml), atractyloside (200 µM), and SHAM (100 µM) were added to the culture after 24 h IPMK knockdown. Tet, 0.5 µg/ml. Data are represented as means. \**p* \< 0.05; \*\**p* \< 0.01, \*\*\**p* \< 0.005 comparing tet- conditions treated with inhibitors vs. tet- cells not treated (No inhibitor) by *t* test.](mbc-29-1137-g007){#F7}

Regulation of energy metabolism is essential for BF-to-PF development
---------------------------------------------------------------------

Because the metabolic and transcriptional changes in *T. brucei* BF after IPMK knockdown preceded development to PFs, we hypothesized that competence for BF-to- PF development is determined, at least in part, by *T. brucei* BFs attaining a metabolic state that favors the transition between the two stages. We tested this hypothesis by genetic and exogenous perturbation of *T. brucei* BF energy metabolism followed by analysis of cell development. After 36 h of IPMK knockdown under BF conditions, we transferred BF cells to SDM-79 at 27°C in the presence of various concentrations of CCA and monitored EP procyclin expression by flow cytometry after 3 d. About 35% of the IPMK knockdown *T. brucei* cells expressed EP procyclin even in the absence of CCA, and the proportion expressing procyclins increased steadily, reaching 83% in 6 mM CCA ([Figure 8, A and B](#F8){ref-type="fig"}). Reexpression of IPMK after BF transfer to PF conditions resulted in a slightly lower rate of EP expression (also noted in [Figure 1C](#F1){ref-type="fig"}), but also, 81% of the cells expressed EP procyclin in 6 mM of CCA. Not only did these cells express procyclins, but also, most of them had a PF morphology. In contrast, continuous expression of IPMK resulted in a lower proportion of *T. brucei* expressing EP procyclin, reaching only ∼33% in 6 mM of CCA. Thus, IPMK knockdown increased the proportion of *T. brucei* BFs that are competent to develop to PFs in response to CCA.

![Regulation of *T. brucei* energy metabolism is essential for development competence. (A) Flow cytometry analysis and quantification of cells expressing EP procyclin after IPMK knockdown in BF for 36 h in HMI-9 at 37°C followed by 3 d in SDM-79 at 27°C in the presence of (B) CCA (0.1--6 mM) or (C) antimycin (8 mM). Tet, 0.5 µg/ml. Data are represented as mean ± SEM.](mbc-29-1137-g008){#F8}

Other TCA cycle intermediates, such as malate, α-ketoglutarate, fumarate or succinate, or myo-inositol, had no significant effect on the development of *T. brucei* SM427 (parental line) or IPMK CNs (Supplemental Figure S7). The effect of CCA is perhaps due to their uptake by specific transporters ([@B17]) and/or CCA activation of proteins involved in development ([@B52]). In contrast, addition of antimycin, which inhibits oxidative phosphorylation, decreased *T. brucei* EP procyclin expression by 41% ([Figure 8C](#F8){ref-type="fig"}). This indicates that production of an active oxidative phosphorylation system is essential for BF *T. brucei* to develop to PF, in agreement with previous data showing that mitochondrial activity is required for development ([@B54]). Hence, IPMK knockdown altered *T. brucei* energy metabolism and increased the competence of BFs to develop into PFs, and this was decreased by perturbation of oxidative phosphorylation.

DISCUSSION
==========

We show here that IPMK functions in regulating *T. brucei* development. IPMK gene knockdown in BFs results in loss of VSGs and expression of procyclins, alteration of glycosomes, production of an active mitochondrial oxidative phosphorylation system, and subsequently morphological changes to PFs. The development is enhanced by addition of TCA cycle metabolites, accompanied by differential expression of RBPs and a PF transcriptome profile. In addition, proteins with roles in cell signaling, metabolism, and protein synthesis and turnover are affinity-enriched by Ins(1,4,5)P3 and Ins(1,3,4,5)P4, the substrate and product of IPMK. A possible explanation is that IPMK function within the complex regulatory network that controls *T. brucei* development, perhaps via interactions of IPs with metabolic and/or regulatory proteins. Perturbation of the network, such as by changes in IPMK expression (or enzyme activity/interactions), may alter IP metabolite levels and perhaps their subcellular locations. These alterations may impact specific IP binding by proteins of the network, which may affect their functions, such as enzymatic activity, protein interactions, and/or subcellular location. Such "second messenger regulation" has been reported in other systems ([@B50]; [@B45]; [@B59]). These changes can result in a cascade of events such as activation of signaling proteins and changes in gene expression, such as mRNA turnover, that further remodels cell meta­bolism, such as production of an active oxidative phosphorylation system, to establish a physiological state that favors BF-to-PF development.

The regulation of BF-to-PF development entails processes that may be coordinated by successive steps of the IP pathway. The IPMK substrate Ins(1,4,5)P3 is the product of PLC. Overexpression of PLC or knockdown of PIP5K or PIP5Pase 1, which respectively produce and eliminate PLC\'s substrate ([Figure 1B](#F1){ref-type="fig"}), dysregulate monoalellic expression of telomeric VSG genes and VSG switching ([@B11]). Regulation of VSG expression revolves around PI phosphorylation at position 5 ([@B11]). However, BF-to-PF development appears to involve IPMK, which phosphorylates Ins(1,4,5)P3 at position 3 and/or 6 ([@B8]). Our previous enzymology analysis showed that *T. brucei* IPMK phosphorylates Ins(1,4,5)P3 to generate Ins(1,3,4,5)P4 and also Ins(1,3,4,5,6)P5 ([@B8]), which was confirmed by others ([@B16]). *T. brucei* IPMK has low amino acid--sequence homology with human IPMK but conserves the catalytic residues, which are also conserved among yeast, *Arabidopsis*, *Plasmodium*, and *Drosophila* ([Figure 2A](#F2){ref-type="fig"}; [@B8]). The results from the IMPK D142A/K144A double mutant, which was unable to phosphorylate Ins(1,4,5)P3 and Ins(1,3,4,5)P4, demonstrate that the role of IPMK in *T. brucei* development involves its catalytic activity. Although further metabolomics analysis is needed to determine the in vivo consequences of IPMK knockdown for IP metabolites and their fluxes, the data suggest that IPMK expression and its effects on IP phosphorylation are involved in the regulation of BF-to-PF developmental processes. It is possible that IPMK may have other noncatalytic functions, such as protein associations, that are involved in the regulation of energy metabolism and development in *T. brucei*. Human IPMK interacts with TOR complex 1 to regulate amino acid signaling ([@B29]), and glucose induces phosphorylation of IPMK as well as its interaction with and down-regulation of AMPK ([@B1]). *T. brucei* AMPK and TOR complexes are involved in BF slender to stumpy development in response to AMP and oxidative stress ([@B2]; [@B43]), although it is not known whether *T. brucei* IPMK interacts with these complexes. IPMK also regulates the switching between glycolysis and oxidative phosphorylation in yeast and mammalian cells ([@B50]) via its interaction with a partner of the Arg80-Mcm1 transcriptional complex that controls Pol II transcription of some metabolic genes. Although *T. brucei* lacks Pol II transcriptional control, it regulates mRNA levels posttranscriptionally ([@B14]), and IPMK and IPs may regulate mRNA nuclear export, as has been shown in yeast and mammalian cells ([@B62]; [@B58]). Hence, IPMK catalytic and perhaps noncatalytic roles are involved in the regulation of *T. brucei* developmental processes.

While typically a very small proportion of cells develop into PF (∼1--3%), IPMK knockdown and its inactivation both resulted in nearly 40% of the cells developing into PFs ([Figure 1, C and D](#F1){ref-type="fig"}). The knockdown of other IP pathway genes, PIP5K, PIP5Pase 1, or CDS, did not result in BF-to-PF development. Thus, it appears that specific perturbation of the IP pathway via IPMK function results in development of PFs. Also, addition of CCA after IPMK knockdown increases the proportion of cells that develop into PFs to 83% ([Figure 8](#F8){ref-type="fig"}). The addition of CCAs, which are TCA--cycle intermediates, may affect the intracellular abundance of metabolites ([@B37]) or activate signaling proteins ([@B52]) and further impact cell development. Although a substantial proportion of cells developed into PFs and survived for nearly 3 wk, they could not be cultivated continuously. This is likely because the cell line used in these studies is derived from the 427 strain, which can develop into PFs if stimulated by CCA, but is unable to be continuously cultivated for unknown reasons ([@B37]). The manipulation of the *IPMK* gene may have affected the cell\'s regulatory network that controls development and thus the increased cell\'s sensitivity to CCA.

IPs can function as second messengers via binding to proteins, which regulates their functions ([@B32]). BF proteins that were affinity-enriched with the IPMK substrate or product are associated with various processes ([Figure 6C](#F6){ref-type="fig"}), as seen in other eukaryotes ([@B59]; [@B28]). Some of the enriched proteins have IP- or PI-binding domains, such as PH or Phox domains (Supplemental Dataset S2), but others lack such domains, perhaps reflecting the limited number of such characterized domains or low sequence conservation in *T. brucei* proteins. We confirmed some of the IP-protein interactions which included proteins involved in metabolism, DNA binding, flagellar function, protein folding and translation. Further validations of these interactions, such as by mutational analysis of potential interacting domains and IP binding assays, will be important to assess their functions in *T. brucei*. Although further studies are necessary to comprehensively identify IP interactomes, our data indicate potential roles for protein interactions and IP metabolites. Generally, *T. brucei* proteins enriched by Ins(1,4,5)P3 are associated with cell motility, flagellum and cytoskeleton organization whereas those enriched by Ins(1,3,4,5)P4 are associated with metabolism, such as glycolysis, amino acid metabolism, purine synthesis, and the TCA cycle, namely processes that differ between BF and PF. Thus IP-protein interactions may function in the control of developmental processes in *T. brucei*, perhaps by affecting protein activity and/or interactions.

*T. brucei* energy metabolism is developmentally regulated, with BFs relying on glycolysis and PFs on oxidative phosphorylation. BFs only have complexes I (NADH: ubiquinone oxidoreductase) and V (F0F1 ATPase/ATP synthase), and the latter hydrolyzes rather than generates ATP ([@B44]). IPMK knockdown in BFs results in increased ATP production that is sensitive to oxidative phosphorylation inhibitors of complexes I, III (coenzyme Q: cytochrome c oxidoreductase), IV (cytochrome c oxidase), and V. The production of ATP by these inhibitor-sensitive complexes correlated with the up-regulation of genes encoding respiratory chain proteins expressed by PFs, which also requires the PF type of editing of mRNAs that are encoded in mitochondrial DNA ([@B22]). Although IPMK knockdown had little effect on pyruvate production or glycosome numbers, PGK signal was somewhat diffuse in the cytosol, probably due to down-regulation of the glycosomal PGKC. Other glycosomal proteins appeared unaffected, suggesting that protein sorting to this organelle was not affected. These changes in mitochondrial and glycosome content and function that occur in BFs after IPMK knockdown resemble the differences between the BF and PF stages. The metabolic changes may explain the lethality of IPMK knockdown to *T. brucei* BFs, given that perturbation of glycosomal function is toxic to BFs ([@B4]; [@B24]). Nevertheless, other factors independent of oxidative phosphorylation or carbon metabolism may also contribute to ATP changes. Further metabolomics studies would be necessary to unravel all metabolic changes associated with IPMK knockdown, given the broad role of IPMK in regulating metabolism ([@B50]; [@B1]), gene expression and nuclear mRNA export ([@B62]; [@B6]) and polyphosphate production ([@B23]; [@B16]).

The transcriptome changes that follow IPMK knockdown also parallel differences between BF and PF cells, including those associated with glucose and carboxylic acid transport, pyruvate and acetyl-coA metabolism, ATP synthesis and cAMP signaling, and surface proteins. *T. brucei* gene expression is primarily regulated posttranscriptionally and RBPs play a role in this process ([@B30]; [@B60]; [@B36]). Overexpression of RBP6, RBP7A or PPCT1 affect expression of BF and PF gene sets that we found were also upregulated after IPMK knockdown. The mechanism by which IPMK affects gene expression in *T. brucei* is unknown. IPMK may regulate gene expression by direct association with RNAs or alternatively by production of IPs that may regulate processes involved in RNA posttranscriptional control; for example, IPMK is involved in regulating nuclear mRNA export in yeast and mammalian cells ([@B62]; [@B58]). Alternatively, *T. brucei* may have a regulatory system that integrates cell metabolism and RBP function, which controls mRNA transport, stability, or degradation, perhaps analogously to riboswitches in prokaryotes ([@B25]). The RBP effects on PF and BF gene sets are dependent on growth conditions, such as medium composition and temperature, suggesting that changes in cell physiology may impact RBP function and gene expression. Such types of regulation were shown by the knockdown of mitochondrial metabolic enzymes or hypoxia, which affect *T. brucei* gene expression ([@B56]), and by the identification of a 25nt glycerol-responsive element in the 3′-UTR of GPEET procyclin mRNAs that regulates its developmental expression ([@B57]). We did not find conserved nucleotide sequences in the 3′ or 5′-UTRs of genes that were differentially regulated after IPMK knockdown, although structural conformations of these UTRs may affect their interactions with RBPs or regulatory proteins.

Only a portion of the BF population developed to PFs after IPMK knockdown, perhaps due to heterogeneity within the cell population, that is, asynchrony of cell cycle, transcriptome, or metabolome, which suggests that a particular physiological state may be needed for *T. brucei* BFs to develop into PFs. This may be the case for stumpy BFs, which are apparently preadapted to develop into PFs ([@B33]). The changes in energy metabolism and transcriptome resulting from IPMK knockdown may have affected the proportion of cells that are competent to develop. This was illustrated by an increase in development of IPMK knockdown cells in the presence of CCA or a decrease by inhibition of oxidative phosphorylation. Such a physiological state is also reflected by dramatic changes in expression levels of metabolic proteins during *T. brucei* BF-to-PF development ([@B54]; [@B19]; [@B18]). Hence, the competence for development appears to be affected by the cell\'s physiological state, which can be altered by IPMK knockdown. This competence is likely a temporal condition that anticipates cells' commitment to development. Reexpression of IPMK after its knockdown did not prevent BF-to-PF development, which implies that some cells committed to this process. This commitment may result from a combination of factors such as signal transduction, metabolic changes, proteins turnover, and changes in gene expression ([@B60]; [@B19]). IPMK overexpression did not affect development, perhaps due to some feedback regulation or posttranslational modification that maintains control of IPMK function. IPMK expression does not appear to change during development to PFs ([@B27]), but its activity, which is critical for BF-to-PF development, could be posttranslationally regulated.

The early evolutionary divergence of *T. brucei* (Excavata) from opisthokonts suggests that the IPMK role in energy metabolism and development, which seems conserved among *T. brucei*, yeast, and mammals, likely appeared early in evolution. However, the divergent mechanisms of *T. brucei* gene regulation, which depends on posttranscriptional processes for control of genes transcribed by RNA polymerase II, and its reliance on RNA polymerase I for transcription of certain protein coding genes suggest that aspects of the processes that regulate the development may also be divergent in *T. brucei*, as they may be in other parasitic protozoa with complex life cycles, such as *Leishmania*, *Plasmodium*, and *Toxoplasma*.

MATERIALS AND METHODS
=====================

Cell culture, transgenic cell lines, and growth curves
------------------------------------------------------

*T. brucei* SM427, null, CN, and V5-tagged cell lines were generated and maintained in HMI-9 at 37°C with 5% CO~2~ as previously described ([@B11]; [@B8]). Gene IDs and product descriptions are Tb927.9.12470, inositol polyphosphate multikinase (IPMK; [@B11]); Tb927.4.1620, phosphatidylinositol 5-kinase 1 (PIP5K 1; [@B11]); Tb927.11.6270, phosphatidylinositol (4,5)/(3,4,5)-phosphate 5-phosphatase (PIP5Pase 1; [@B11]), Tb927.7.220, CDP-diacylglycerol synthase ([@B11]); Tb927.9.5680; phosphatidylinositol 5-phosphatase (PIP5Pase 2; [@B8]); Tb927.10.5510, inositol polyphosphate 5-phosphatase (IP5Pase; [@B8]); Tb927.8.7170, inositol polyphosphate 1-phosphatase (IP1Pase; Supplemental Figure S4); Tb927.9.6350, inositol-1(or -4)-monophosphatase 2 (IMPase 2; [@B8]); and Tb927.7.3490, synaptojanin (IP or PI 5-phosphatase) 2 (SYJ 2; Supplemental Figure S4). For generation of IPMK CN exclusively expressing WT or mutant versions (D142A, K164W, or D142A/K144A) of IMPK, the IPMK genes were amplified from pET-29-IPMK WT or mutants (see *Recombinant protein and enzymatic activity* for details on the generation of mutated IPMK) using the forward and reverse primers, respectively CCCGGTCTCAAGCTTATGTTAAATA­TTTGC­CAAAACTTGTCTTC and CCCGGTCTCGGATCCTGAAAG­AAGA­AAAATAATTTTTTCCA, and cloned into pHD-tub-3V5 vector using the *Hin*dIII and *Bam*HI sites. Plasmids were integrated into the constitutive tubulin locus by cell electroporation and puromycin resistance selection. Cumulative growth curve analyses were performed as previously described ([@B11]). Briefly, *T. brucei* BFs diluted daily to 5.0 × 10^4^ parasites/ml were grown in the presence or absence of tet (0.5 µg/ml) and counted daily using a cell counter (Beckman), and the procedure was repeated for five to seven consecutive days.

Viability analysis
------------------

Viability assays were performed as previously described ([@B10]). Briefly, compound stocks were prepared at a 10 mM--1 M concentration in dimethyl sulfoxide (DMSO) or ethanol. *T. brucei* BF (100 µl at 2.0 × 10^4^ parasites/ml) was plated in 96-well plates and mixed with 100 µl of compounds at twofold serial dilutions: SHAM (100--0.2 mM), oligomycin (10--0.02 µg/ml), sodium azide (40--0.08 µM), antimycin (40--0.08 µM), rotenone (100--0.2 µM), and potassium cyanide (100--0.2 µM), all diluted in HMI-9 medium with 10% fetal bovine serum (FBS). Parasites not treated with compounds were also plated as controls. After 36 h of incubation at 37°C and 5% CO~2~, 20 µl of alamarBlue (Invitrogen) was added, and the assays were developed for 4 h. Fluorescence measurements were obtained using a SpectraMax M2 microplate reader (Molecular Devices) with excitation at 544 nm and emission at 590 nm (590-nm cutoff). Data were analyzed using GraphPad Prism for Windows.

IF and Western blot analysis
----------------------------

For IF, mid--log phase *T. brucei* were fixed with 2% paraformaldehyde (PFA) in phosphate-buffered saline (PBS), adhered to a poly-[l]{.smallcaps}-lysine--treated 2-mm cover glass (Fisher), permeabilized with 0.2% NP40 in PBS for 5 min, and blocked for 1 h with 3% BSA in PBS. Cells were incubated for 2 h at room temperature (RT) with pAb α-PGK (1789G), α-gGAPDH/Aldolase (2481D), or mAbs α-EP procyclin, clone tbrp1/247 (Cedarlane Laboratories), followed by goat α-rabbit or goat α-mouse immunoglobulin G (IgG) (H+L)--Alexa Fluor 488 or 568 (Molecular Probes); see Supplemental Table S1 for all antibody dilutions. DNA was stained with 1 µg/ml 4′,6-diamidino-2-phenylindole (DAPI; Sigma) and slides mounted with ProLong Gold Antifade Reagent (Life Technologies). Images were acquired with a Deltavision 3D deconvolution microscope (Olympus IX70) and analyzed with Softworks software (Applied Precision). Western blots were performed as described previously ([@B11]). Briefly, lysates of *T. brucei* BF in 1% Triton X-100 in PBS with a protease inhibitors cocktail (Roche) were separated in 4--20% Mini-PROTEAN TGX gel (Bio-Rad) and transferred to immobilon-P PVDF (Millipore). Membranes were probed overnight (ON) at 4°C with abs α-PGK, α-gGAPDH/Aldolase, α-HSP70, α-AOX, α-Pex14, α-procyclins, or α-VSGs, followed by goat α-rabbit or goat α-mouse IgG (H+L) conjugated to horseradish peroxidase (HRP) and developed by chemiluminescence.

Recombinant protein and enzymatic activity
------------------------------------------

The *T. brucei* gene encoding IPMK was cloned into pET-29a (Novagen) and expressed and purified from *E. coli* DE3 pLysS Rosetta cells (Novagen) as previously reported ([@B8]). Site-directed mutagenesis of IPMK was performed using the pET-29-IPMK construct and a Q5 site-directed mutagenesis kit (New England Biolabs) according to the manufacturer\'s instructions. The forward and reverse primers used in site-direct mutagenesis reactions were as follows: D142A: TTGTGTGCTTGCTATCAAACTTG and GGTTTATGAAATGTCGCG, K164W: GCGCATACATTGGAGGCAGCTTC and TCCACCTTGTCGGGTAAT, and D142A/K144A: GCTTGCTATCGCACTTGGATATGTG and ACACAAGGTTTATGAAATGTC. Protein activity was assayed in 30-µl reactions in 96-well plates in a buffer consisting of 20 mM HEPES, 150 mM NaCl, and 2 mM MgCl~2~ (pH 7.5). The reactions also contained 300 nM rTbIPMK WT or a mutant version thereof, 5--200 mM Ins(1,4,5)P3 or Ins(1,2,4,5)P4 (Echelon Biosciences), and 200 µM of ATP. Reactions were incubated for 60 min at 37°C, after which IMPK activity was measured using the ADP luciferase assay (Promega; [@B8]) and a Glomax plate reader (Promega). Kinetic analyses were calculated by nonlinear regression using GraphPad Prism for Windows 5.03 (GraphPad Software).

IP interactions and proteomic analysis and quantification
---------------------------------------------------------

A sample of 2.0 × 10^9^ mid--log phase *T. brucei* BFs was harvested from 2 l of culture by centrifugation at 4000 rpm for 10 min at RT, resuspended in 1% Triton X-100 in 50 mM Tris, 150 mM NaCl, and 0.2% NP40 with a protease inhibitor cocktail (Roche) and rotated for 15 min at 4°C for complete cell lysis. The resultant lysates were cleared by centrifugation at 14,000 × *g* at 4°C and then incubated with agarose beads conjugated with Ins(1,4,5)P3, Ins(1,3,4,5)P4, or PI(3,4,5)P3 or nonconjugated beads in binding buffer 50 mM Tris, 150 mM NaCl, 0.2% NP40, 5 mM MgCl~2~, pH 7.4, and protease inhibitors (Roche). IPs immobilized on agarose beads were purchased from Echelon Biosciences. Each 1 ml of agarose beads contains 10 nmol of bound IP metabolites as described ([@B28]; [@B59]). For confirmation of IP--protein binding, lysates of 5.0 × 10^7^ mid--log growth *T. brucei* BFs were incubated with biotin-Ins(1,4,5)P3 or biotin-Ins(1,3,4,5)P4 (Echelon Biosciences; biotin linked through the 1-position on the inositol ring) in binding buffer (as above) followed by incubation with 50 µl of Dynabeads M-270 Streptavidin (ThermoFisher Scientific). After 2 h rotation at 4°C the beads were washed with 50 mM Tris, 300 mM NaCl, 0.2% NP40, and 5 mM MgCl~2~, pH 7.4, and fractions were eluted with Laemmli sample buffer with 5% β-mercaptoethanol. Samples were separated in 4--20% SDS--PAGE and transferred for Western blot analysis or precipitated with cold acetone and processed for mass spectrometry as described ([@B9]). Mass spectrometry analyses were performed at the Fred Hutchinson Cancer Research Center using an LTQ-OrbiTrap. MaxQuant was used for peptide and protein identification with mass tolerance of ±10 ppm, fragment mass tolerance of ±0.5 Da, monoisotopic mass values, C13 = 2, against the *T. brucei* v5.0 predicted protein sequence database. Label-free quantitative analysis was performed using the R package MSstats by comparing each IP--protein interaction against agarose beads--protein interactions as described by [@B15]. Data include three biological replicates for affinity purifications with nonconjugated agarose beads; three biological replicates for Ins(1,4,5)P3-agarose conjugate beads; two biological replicates for Ins(1,3,4,5)P4-agarose conjugated beads; and two biological replicates for PI(3,4,5)P3-agarose conjugated beads. See Supplemental Dataset 2 for a list of all proteins and peptides identified. The proteomics data have been deposited with the ProteomeXchange Consortium via the PRIDE partner repository with the data set identifier PXD005907.

RNA analysis and sequencing
---------------------------

Mid--log phase CN cell lines were grown with or without 0.5 µg/ml tet for 24 and 36 h and harvested at RT (10 min, 1300 × *g*) and RNAs were extracted using TRIzol (Life Technologies). Real-time PCR was performed as described by [@B11]. Supplemental Table S2 lists the primers. RNAseq of poly-A enriched RNAs was performed as described by [@B31]. Libraries were sequenced at the Department of Genome Sciences, University of Washington, on two biological replicates for each experiment (see Supplemental Table S3 for a detailed description of library sequences and a biological replicate correlation analysis). Reads alignment and gene ID mapping were done using Bowtie2 and HTSeq, respectively, against the *T. brucei* 427 genome tritrypDB version 9. Read counts were obtained with Get_ReadCount.py and differential gene expression using edgeR ([@B40]) using a likelihood ratio test ([@B34]). A minimum of one count per million (CPM) per gene, that is, five counts per gene in the smallest library, and counts represented in at least two biological replicate libraries were required for a gene to be considered for analysis. Genes were considered differentially expressed when fold changes were ≥2 and *p* values ≤ 0.05 (Supplemental Dataset S1). Data have been deposited to the SRA repository with the data set identifiers SRR5314671, SRR5314672, SRR5315219, and SRR5315220. GSEA was performed using the phenoTest package in R ([@B48]; [@B38]). Gene sets were constructed with genes that are differentially expressed in BF slender, intermediate, stumpy, and PFs ([@B7]), and include genes that are up-regulated (72 genes) or down-regulated (254 genes) in BF stumpy compared with BF slender; and up-regulated (130 genes) or down-regulated (178 genes) in BF intermediate compared with BF slender. It also includes sets of genes that are up-regulated in BF compared with PF (157 genes) or PF compared with BF (70 genes). Gene sets were analyzed using 1000 permutation tests by comparing gene sets against the RNAseq data of IPMK knockdown at 36 h. False discovery rates (*q*) were calculated by the Benjamini--Hochberg procedure and significance indicated by *q-*value \<0.05. Gene sets were represented using a barcode plot using the Limma package in R ([@B39]).

Metabolic analysis
------------------

IP pathway genes were knocked down for 24 and 48 h, and cells (100 µl) were incubated with a 100 µl CellTiter-Glo luminescent cell viability assay (Promega) to measure ATP using a GloMax 96-microplate lLuminometer (Promega). In parallel, cell supernatants were quantified using a pyruvate assay kit, both according to manufacturer\'s instructions (Eton Bioscience). Antimycin (8 mM), K cyanide (50 µM), sodium azide (0.5 mM), rotenone (5 µM), oligomycin (50 µg/ml), atractyloside (200 µM), and SHAM (100 µM) were incubated with CN IPMK 24 h after knockdown and ATP was measured at 48 h as described above.

Development assays and flow cytometry analysis
----------------------------------------------

*T. brucei* IPMK, PIP5K, PIP5Pase 1, or CDS CNs were grown (∼1.5 × 10^6^ parasites/ml) with or without tet (0.5 µg/ml) for 36 h in 40 ml HMI-9 medium at 37°C and 5.0 × 10^7^ parasites were transferred to 2 or 10 ml SDM-79 and cultured for 3 or 10 d at 27°C. Cells were counted every 2 d by monitoring BF or PF morphology under light microscopy in Neubauer chambers. Aliquots of 1 ml of cells were collected at days 3 and 4 for EP procyclin expression analysis by fluorescence microscopy (see above) or by flow cytometry (details below). *T. brucei* IPMK CN BFs or SM427 were also incubated in CCA (0.16, 0.5, 1, 3, and 6 mM) or 8 mM antimycin, malate (10 mM), α-ketoglutarate (10 mM), succinate (10 mM), or myo-inositol (10 mM) upon transfer to SDM-79 medium at 27°C; then procyclin expression were analyzed after 3 d by flow cytometry. For procyclin analysis after IPMK overexpression, *T. brucei* BF that express tet-regulatable C-terminally V5-tagged IPMK were grown at late log phase (∼1.5 × 10^6^ parasites/ml) without tet in HMI-9 at 37°C for 24 h. Afterward, cells were transferred to 24-well plates at 2.0 × 10^7^ parasites/ml without or with tet (1 µg/ml) and cultured in SDM-79 at 27°C for 3 d in the presence of various concentrations of CCA (0.16, 0.5, 1, 3, and 6 mM). Aliquots of 1 ml of culture were fixed in 2% PFA, blocked for 1 h with 3% BSA in PBS, and incubated for 2 h with mAbs α-EP procyclin (Cedarlane Laboratories; see Supplemental Table S1 for antibody dilutions). These cells were washed three times with PBS, incubated for 1 h with mAbs α-mouse IgG--Alexa Fluor 488 (Molecular Probes; see Supplemental Table S1), and washed three times with PBS. Ten thousand cells in PBS were analyzed by flow cytometry using a BD LSR II flow cytometer (BD Biosciences) and FlowJo software (Flowjo). For exclusive expression of *Trypanosoma cruzi* or *Leishmania major* IPMK, *T. brucei* IPMK CN constitutively expressing *L. major* or *T. cruzi* IPMK allele introduced in the tubulin locus ([@B8]) were grown at late log phase (∼1.5 × 10^6^ parasites/ml) with tet (0.5 µg/ml) for 36 h in 40 ml HMI-9 medium at 37°C. Afterward, cells were washed and 2 ml aliquots were transferred to 24-well plates at 2.0 × 10^7^ parasites/ml without or with tet (1 µg/ml) and cultured in SDM-79 at 27°C for 3 d. Cells were fixed and stained with α-EP procyclin antibodies and analyzed by flow cytometry (all as described above). For PAD1 analysis, *T. brucei* IPMK CN were grown at late log phase (∼1.5 × 10^6^ parasites/ml) with or without tet (0.5 µg/ml) for 24 and 36 h in 40 ml HMI-9 medium at 37°C. Then 10-ml aliquots were fixed in 1% PFA and blocked in PBS 10% FBS (vol/vol) for 1 h at RT. Cells were washed three times in PBS, incubated in PBS 5% FBS (vol/vol) with pAb α-PAD1 (see Supplemental Table S1) for 2 h at RT, washed three times in PBS, and then incubated with goat α-rabbit IgG (H+L)--Alexa Fluor 568 (Molecular Probes; see Supplemental Table S1) as indicated above. Cells were washed three times in PBS and analyzed by flow cytometry as described.

Data presentation and statistical analysis
------------------------------------------

Data are shown as means ± SEMs of at least three biological replicates unless otherwise stated. Comparisons among groups were made by a two-tailed *t* test using GraphPad Prism. *P* values \<0.05 with a confidence interval of 95% were considered statistically significant unless otherwise stated. Graphs were prepared using GraphPad Prism (GraphPad Software) or RStudio ([@B53]).

Supplementary Material
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

This article was published online ahead of print in MBoC in Press (<http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E17-08-0515>) on March 5, 2018.

This work was supported by National Institutes of Health Grant R01AI078962 to K.S. and Supplement R01AI014102-37S1 to K.S. and I.C. and by the Center for Infectious Disease Research. We thank Marilyn Parsons for comments on the manuscript and for providing antibodies against Pex14, PGK, GAPDH, Aldolase, and PAD1, Anna Wrem for administrative support, and Lindsay N. Carpp for technical editing of the manuscript.

BF

:   bloodstream form

CCA

:   citrate and *cis*-aconitate

CN

:   conditional null

IP

:   inositol phosphate

IPMK

:   inositol polyphosphate multikinase

PF

:   procyclic form

PI

:   phosphatidylinositol

RBP

:   RNA-binding proteins

TCA

:   tricarboxylic acid

VSGs

:   variant surface glycoproteins
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